Tingyu H. Wang

Tianjin, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 58 publications

Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001).

Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 27, 2026

MYD88 variants in chronic lymphocytic leukemia exhibit distinct biological behaviors and prognostic implications.

MYD88 variants in chronic lymphocytic leukemia exhibit distinct biological behaviors and prognostic implications.

Journal: Leukemia
Published: December 10, 2025

Disease characteristics, treatment, and outcomes in Chinese chronic lymphocytic leukemia patients following BTK inhibitor discontinuation: a multicenter real-world study.

Disease characteristics, treatment, and outcomes in Chinese chronic lymphocytic leukemia patients following BTK inhibitor discontinuation: a multicenter real-world study.

Journal: Frontiers in medicine
Published: November 04, 2025

The prognostic implications of autoimmune hemolytic anemia in chronic lymphocytic leukemia across treatment eras.

The prognostic implications of autoimmune hemolytic anemia in chronic lymphocytic leukemia across treatment eras.

Journal: Haematologica
Published: October 28, 2025

Ibrutinib alternating with three cycles of interval fludarabine, cyclophosphamide, and rituximab (FCR) in adults with untreated chronic lymphocytic leukaemia as time-limited regimen: a single-arm, multicentre phase 2 trial in China.

Ibrutinib alternating with three cycles of interval fludarabine, cyclophosphamide, and rituximab (FCR) in adults with untreated chronic lymphocytic leukaemia as time-limited regimen: a single-arm, multicentre phase 2 trial in China.

Journal: EClinicalMedicine
Published: August 15, 2025

Prognostic significance of clinical risk models and genomic alterations in Waldenström macroglobulinemia before or after the BTK inhibitor era.

Prognostic significance of clinical risk models and genomic alterations in Waldenström macroglobulinemia before or after the BTK inhibitor era.

Journal: Leukemia
Published: August 10, 2025

Obinutuzumab plus bendamustine as first-line therapy for indolent B-cell lymphomas: a prospective multicenter open-label study.

Obinutuzumab plus bendamustine as first-line therapy for indolent B-cell lymphomas: a prospective multicenter open-label study.

Journal: MedScience
Published: August 06, 2025

Monoclonal gammopathy defines distinct clinical subsets in chronic lymphocytic leukemia across therapeutic eras.

Monoclonal gammopathy defines distinct clinical subsets in chronic lymphocytic leukemia across therapeutic eras.

Journal: Blood advances
Published: May 07, 2025

Identification of a CAR-Derived Clone by NGS-Based MRD After Fully Human BCMA CAR T-Cell Therapy in Multiple Myeloma.

Identification of a CAR-Derived Clone by NGS-Based MRD After Fully Human BCMA CAR T-Cell Therapy in Multiple Myeloma.

Journal: American journal of hematology
Published: April 24, 2025

Comparative analysis of patients' characteristics, treatment, and survival outcomes in CLL from China and the United States.

Comparative analysis of patients' characteristics, treatment, and survival outcomes in CLL from China and the United States.

Journal: The oncologist
Published: April 01, 2025

Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma.

Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma.

Journal: The Journal of clinical investigation
Published: March 17, 2025

Continuous R-DA-EDOCH alternated with high-dose Ara-C induces deep remission and overcomes high-risk factors in young patients with newly diagnosed mantle cell lymphoma.

Continuous R-DA-EDOCH alternated with high-dose Ara-C induces deep remission and overcomes high-risk factors in young patients with newly diagnosed mantle cell lymphoma.

Journal: Cancer biology & medicine
Published: March 12, 2025
Showing 1-12 of 58

Last Updated: 09/26/2026